Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients wi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 ... the winners of the 2015 BeHEARD science challenge, a ... offers rare disease researchers, access to the latest life ... its drug repositioning and pathway analytics capability to support ... Nation Foundation in the study of Niemann-Pick Disease Type ...
(Date:9/2/2015)... 2, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), ... urological and related conditions, announced today that it has ... convertible note financing, raising a total of $5.175 million, ... million. Josh Disbrow , Chief ... placement are intended to be used to conduct clinical ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... Diego, CA (PRWEB) , ... September 02, 2015 ... ... troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to analysis ... detailed views of fascinating events that go by too quickly to process with ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... GenVec, Inc. (Nasdaq: GNVC ) today announced that ... Stockholder Rights Plan through the adoption of a new Rights ... on September 7, 2011, which is the date that GenVec,s ... Agreement was adopted in connection with the expiration of the ...
... Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today ... be presenting a corporate overview at the 2011 Wedbush ... 16, 2011, at 8:00 AM ET, in New York. ... on the Investors page of Insmed,s website, http://www.insmed.com ...
... MADISON, Wis., Aug. 11, 2011 Cellular Dynamics International ... Research Grant Program. This grant program will advance researchers, ... cell types derived from them, and the role and ... basic research, drug discovery and development.   ...
Cached Biology Technology:GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference 2Cellular Dynamics Launches Innovative Research Grant Program 2
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... study from Rhode Island Hospital has found that a change ... contribute to improved outcomes of the victims and to the ... enforcement officers often serve as medical first responders, there is ... or should do, at the scene of an overdose. The ...
... MedNet Solutions , a global life sciences technology ... to announce that Accelovance , an award-winning, full-service ... Vaccines and General Medicine development, has joined the ... as an iMedNet Partner will facilitate Accelovance,s ...
... of Helsinki and Folkhlsan Research Center has identified a ... breeds, the Norwegian Elkhound and the Karelian Bear Dog. ... and a candidate gene for human chondrodysplasias. The finding ... health. A genetic test can now be used to ...
Cached Biology News:Changing laws, attitudes of police response to drug overdose may lead to better outcomes 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 3New dwarfism mutation identified in dogs 2
... medium for the detection, isolation, differentiation ... thyphi) and total coliforms from other ... maximum of 24 hours, needs no ... preparation and performs a higher diagnostic ...
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... Dynamic Focusing MALDI (PDF-MALDI) source provides fast, ... do not need online separation. Paired with ... and Agilents powerful Spectrum Mill software, the ... of 2D gel-spot digests. It provides clean, ...
Biology Products: